Literature DB >> 30363508

Predictable Risk Factors for the Feeling of Presence in Patients with Parkinson's Disease.

Hiroshi Kataoka1, Satoshi Ueno1.   

Abstract

BACKGROUND: The detailed relations between feeling of presence (FOP) and hallucinations remain uncertain in Parkinson's disease (PD). The prospective studies of risk factors predicting the onset of FOP have yet to be reported on. We prospectively investigated risk factors for FOP to identify factors related to the development of first-onset hallucinations from FOP in patients with PD who were followed up for 2 years.
METHODS: From among the 100 consecutive patients, we registered 78 patients with PD. Once every 1 to 3 months, the same sole interviewer personally asked these patients during 2 years of follow-up. Seventeen independent variables were evaluated using multivariate logistic regression analysis using forced entry.
RESULTS: Seventeen patients newly presented with FOP. In 7 patients, hallucinations developed after the onset of FOP. Twenty-six patients newly presented with visual hallucinations. On multivariate logistic regression analysis, the score for UPDRS part 4 (odds ratio [OR] = 1.413; P = 0.049; 95% confidence interval [CI] = 1.002-1.991) and an increase in dose of antiparkinsonian medications (OR = 0.132; P = 0.033; 95% CI = 0.021-0.846) were related to onset of FOP. Zung depression score (P = 0.017) differed significantly between patients who had FOP without hallucinations and those who had FOP with hallucinations (39.2 ± 5.21 and 46.25 ± 2.86, respectively).
CONCLUSION: Motor complications and increasing doses of antiparkinsonian medications may predict onset of FOP, and depression might be helpful for predicting the future development of hallucinations from FOP.

Entities:  

Keywords:  Parkinson; feeling of presence; hallucination; neurodegenerative disease; predictable factor

Year:  2015        PMID: 30363508      PMCID: PMC6178595          DOI: 10.1002/mdc3.12233

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  13 in total

1.  Hallucinations in Parkinson's disease. prevalence, phenomenology and risk factors. Fenelon G* mahieux F, huon R, Ziegler M. Brain 2000;123:733-745

Authors: 
Journal:  Am J Ophthalmol       Date:  2000-08       Impact factor: 5.258

2.  The Parkinson fatigue scale.

Authors:  R G Brown; A Dittner; L Findley; S C Wessely
Journal:  Parkinsonism Relat Disord       Date:  2005-01       Impact factor: 4.891

Review 3.  [Musical hallucinations: 7 cases].

Authors:  G Fénelon; S Marie; J P Ferroir; A Guillard
Journal:  Rev Neurol (Paris)       Date:  1993       Impact factor: 2.607

4.  Feeling of presence in Parkinson's disease.

Authors:  Gilles Fénelon; Thierry Soulas; Laurent Cleret de Langavant; Iris Trinkler; Anne-Catherine Bachoud-Lévi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-05-07       Impact factor: 10.154

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.

Authors:  D Aarsland; J P Larsen; J L Cummins; K Laake
Journal:  Arch Neurol       Date:  1999-05

7.  Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group.

Authors:  Bernard Ravina; Karen Marder; Hubert H Fernandez; Joseph H Friedman; William McDonald; Diane Murphy; Dag Aarsland; Debra Babcock; Jefferey Cummings; Jean Endicott; Stewart Factor; Wendy Galpern; Andrew Lees; Laura Marsh; Mark Stacy; Katrina Gwinn-Hardy; Valerie Voon; Christopher Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

8.  Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias?

Authors:  A Minguez-Castellanos; F Escamilla-Sevilla; M J Katati; J M Martin-Linares; M Meersmans; A Ortega-Moreno; V Arjona
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

9.  Risk factors for hallucinations in Parkinson's disease: results from a large prospective cohort study.

Authors:  Kangdi Zhu; Jacobus J van Hilten; Hein Putter; Johan Marinus
Journal:  Mov Disord       Date:  2013-03-20       Impact factor: 10.338

10.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

View more
  1 in total

1.  Can levodopa prevent cognitive decline in patients with Parkinson's disease?

Authors:  Masahiro Ikeda; Hiroshi Kataoka; Satoshi Ueno
Journal:  Am J Neurodegener Dis       Date:  2017-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.